Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-103611
Filing Date
2025-08-06
Accepted
2025-08-06 10:00:49
Documents
74
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mcrb-20250630.htm   iXBRL 10-Q 2815682
2 EX-10.1 mcrb-ex10_1.htm EX-10.1 16874
3 EX-10.2 mcrb-ex10_2.htm EX-10.2 21448
4 EX-10.3 mcrb-ex10_3.htm EX-10.3 21464
5 EX-31.1 mcrb-ex31_1.htm EX-31.1 15145
6 EX-31.2 mcrb-ex31_2.htm EX-31.2 14903
7 EX-32.1 mcrb-ex32_1.htm EX-32.1 9326
8 EX-32.2 mcrb-ex32_2.htm EX-32.2 9187
  Complete submission text file 0000950170-25-103611.txt   9595605

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20250630.xsd EX-101.SCH 1077717
77 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20250630_htm.xml XML 1703017
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37465 | Film No.: 251187897
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)